Related references
Note: Only part of the references are listed.Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
Qian He et al.
EMERGING MICROBES & INFECTIONS (2021)
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Robert H Shaw et al.
LANCET (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
Kevin R. Bewley et al.
NATURE PROTOCOLS (2021)
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Alexandra J. Spencer et al.
NATURE COMMUNICATIONS (2021)
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Alberto M. Borobia et al.
LANCET (2021)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics
RB D'Agostino et al.
STATISTICS IN MEDICINE (2003)